Details
Stereochemistry | UNKNOWN |
Molecular Formula | C12H18ClN |
Molecular Weight | 211.731 |
Optical Activity | ( + ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CC1=CC=CC=C1)NCCCCl
InChI
InChIKey=XXVROGAVTTXONC-UHFFFAOYSA-N
InChI=1S/C12H18ClN/c1-11(14-9-5-8-13)10-12-6-3-2-4-7-12/h2-4,6-7,11,14H,5,8-10H2,1H3
Molecular Formula | C12H18ClN |
Molecular Weight | 211.731 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3743406Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3743406
Curator's Comment: description was created based on several sources, including, http://ec.europa.eu/health/documents/community-register/2000/200003093430/anx_3430_en.pdf
Mefenorex or (+/-)N-(3-chloropropyl)-1-methyl-2-phenylethylamine is an N-alkylated analogue of amphetamine. The therapeutic efficacy of mefenorex as an adjunctive support in the treatment of obesity for limited periods of time, as well as its ability to be well tolerated, has been amply demonstrated. Mefenorex is considered to be racemic mixture, no available data regarding enantiospecific pharmacological activity of the compound.
CNS Activity
Originator
Sources: http://www.google.ru/patents/DE1210873B
Curator's Comment: # Hoffmann-La Roche
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. | 2002 Apr |
|
Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. | 2002 May |
|
Impaired cognition and attention in adults: pharmacological management strategies. | 2007 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/37853
40 mg/day
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:30:27 GMT 2023
by
admin
on
Sat Dec 16 10:30:27 GMT 2023
|
Record UNII |
85052999IT
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
21777
Created by
admin on Sat Dec 16 10:30:27 GMT 2023 , Edited by admin on Sat Dec 16 10:30:27 GMT 2023
|
PRIMARY | |||
|
111051-41-3
Created by
admin on Sat Dec 16 10:30:27 GMT 2023 , Edited by admin on Sat Dec 16 10:30:27 GMT 2023
|
PRIMARY | |||
|
85052999IT
Created by
admin on Sat Dec 16 10:30:27 GMT 2023 , Edited by admin on Sat Dec 16 10:30:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
RACEMATE -> ENANTIOMER | |||
|
ENANTIOMER -> ENANTIOMER |
|